Literature DB >> 23587956

Drug combinations against Mucor irregularis in vitro.

Shuzhen Zhang1, Ruoyu Li, Jin Yu.   

Abstract

Combinations of terbinafine or caspofungin with amphotericin B, posaconazole, or itraconazole were studied as potential treatments against 18 isolates of Mucor irregularis in vitro. Synergism of the combinations of terbinafine with amphotericin B, posaconazole, and itraconazole against 38.9, 33.3, and 44.4% of the strains studied was observed. In contrast, synergism of the combinations of caspofungin with amphotericin B, posaconazole, and itraconazole against 99.4, 66.7, and 99.4% of the strains studied was observed. Furthermore, no antagonism was observed.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23587956      PMCID： PMC3697376          DOI： 10.1128/AAC.02612-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

1.  In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents.

Authors:  Eric Dannaoui; Javier Afeltra; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

2.  In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Maria J Buitrago; Emilia Mellado; Guillermo Garcia-Effron; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  In vitro evaluation of the type of interaction obtained by the combination of terbinafine and itraconazole, voriconazole, or amphotericin B against dematiaceous molds.

Authors:  Fernanda Simas Corrêa Biancalana; Luzia Lyra; Angélica Zaninelli Schreiber
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

4.  Identification and susceptibility of Rhizomucor spp. isolated from patients with cutaneous zygomycosis in China.

Authors:  Si-Bu Wang; Ruo-Yu Li; Jin Yu
Journal:  Med Mycol       Date:  2011-03-30       Impact factor: 4.076

5.  Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.

Authors:  Ashraf S Ibrahim; Joel C Bowman; Valentina Avanessian; Keturah Brown; Brad Spellberg; John E Edwards; Cameron M Douglas
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

6.  Chronic rhinofacial mucormycosis caused by Mucor irregularis (Rhizomucor variabilis) in India.

Authors:  B M Hemashettar; R N Patil; Kerry O'Donnell; Vishnu Chaturvedi; Ping Ren; Arvind A Padhye
Journal:  J Clin Microbiol       Date:  2011-04-20       Impact factor: 5.948

7.  Antifungal activity of antifungal drugs, as well as drug combinations against Exophiala dermatitidis.

Authors:  Yi Sun; Wei Liu; Zhe Wan; Xiaohong Wang; Ruoyu Li
Journal:  Mycopathologia       Date:  2010-08-29       Impact factor: 2.574

Review 8.  Mucor irregularis infection and lethal midline granuloma: a case report and review of published literature.

Authors:  Dong Ming Li; Li De Lun
Journal:  Mycopathologia       Date:  2012-06-29       Impact factor: 2.574

9.  Rhizomucor variabilis var. regularior and Hormographiella aspergillata infections in a leukemic bone marrow transplant recipient with refractory neutropenia.

Authors:  Mayssa M Abuali; Roberto Posada; Gustavo Del Toro; Elizabeth Roman; Rama Ramani; Sudha Chaturvedi; Vishnu Chaturvedi; Vincent J LaBombardi
Journal:  J Clin Microbiol       Date:  2009-10-21       Impact factor: 5.948

10.  Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B.

Authors:  L Vazquez; J J Mateos; C Sanz-Rodriguez; E Perez; D Caballero; J F San Miguel
Journal:  Haematologica       Date:  2005-12       Impact factor: 9.941
View more
  3 in total

1.  Successful Treatment by Surgery of a Primary Cutaneous Mucormycosis Caused by Mucor irregularis.

Authors:  Guan-Zhao Liang; Wen-Qi Xu; Xiao-Li Zheng; Huan Mei; Gui-Xia Lv; Yong-Nian Shen; Dong-Mei Li; Wei-da Liu
Journal:  Mycopathologia       Date:  2017-10-30       Impact factor: 2.574

2.  The Combination Treatment of Fosmanogepix and Liposomal Amphotericin B Is Superior to Monotherapy in Treating Experimental Invasive Mold Infections.

Authors:  Teclegiorgis Gebremariam; Yiyou Gu; Sondus Alkhazraji; Eman Youssef; Karen Joy Shaw; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2022-06-07       Impact factor: 5.938

3.  Mucor irregularis-associated cutaneous mucormycosis: Case report and review.

Authors:  Blandine Rammaert; Cécile Angebault; Anne Scemla; Sylvie Fraitag; Nathalie Lerolle; Marc Lecuit; Marie-Elisabeth Bougnoux; Olivier Lortholary
Journal:  Med Mycol Case Rep       Date:  2014-07-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.